Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can

  • 0 views
  • 25 Jul, 2022
  • 21 locations
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

  • 56 views
  • 06 Apr, 2022
  • 16 locations
SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.

  • 0 views
  • 19 Jun, 2022
  • 5 locations
Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

(dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or

leiomyosarcoma
cancer chemotherapy
dedifferentiated liposarcoma
systemic therapy
measurable disease
  • 0 views
  • 30 Jul, 2021
  • 23 locations
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1 and Cohort 2) or MRCLS (Cohort 1) .

  • 30 views
  • 11 Jul, 2022
  • 23 locations
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

solid neoplasm
primary cancer
sarcoma
cyclophosphamide
measurable disease
  • 4 views
  • 26 Mar, 2022
  • 35 locations
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

BRAF
primary cancer
sarcoma
ROS1
taxane
  • 0 views
  • 03 May, 2022
  • 16 locations
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma.

systemic therapy
measurable disease
neutrophil count
metastasis
liposarcoma
  • 0 views
  • 04 Jan, 2022
  • 7 locations
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101)

The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma (LPS) and leiomyosarcoma (LMS). ATX-101 is an

docetaxel
leiomyosarcoma
cancer chemotherapy
gemcitabine
systemic therapy
  • 0 views
  • 25 Jul, 2022
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the

growth factor
measurable disease
liposarcoma
  • 0 views
  • 29 Sep, 2021
  • 2 locations